Research location
Kurashiki
Japan
Advertisement
Research activity in Kurashiki
JapanCureCurrent currently publishes aggregate city-level research activity for this location: 20 trials and 20 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Kurashiki
20 linked trials · page 1 of 1A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)NCT07589595 · 2026-05-20 · 1 site observation
RECRUITING
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07 · 1 site observation
RECRUITING
Tezepelumab PRO StudyNCT05922891 · 2023-09-27 · 1 site observation
COMPLETED
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerNCT05388669 · 2022-08-05 · 1 site observation
ACTIVE_NOT_RECRUITING
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyNCT05338970 · 2022-07-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsNCT04538664 · 2020-10-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)NCT04501497 · 2020-08-21 · 1 site observation
COMPLETED
Mid-Q Response StudyNCT04180696 · 2020-01-23 · 1 site observation
COMPLETED
A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)NCT03645330 · 2018-08-15 · 1 site observation
COMPLETED
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerNCT02152631 · 2014-10-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate CancerNCT01756638 · 2012-06-06 · 1 site observation
COMPLETED
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received DocetaxelNCT01795703 · 2012-06-01 · 1 site observation
COMPLETED
Safety and Efficacy of Daily Use of Micamlo® Combination Tablets AP in Patients With HypertensionNCT01353274 · 2011-05-01 · 1 site observation
COMPLETED
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01202188 · 2010-09-01 · 1 site observation
COMPLETED
Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term UseNCT01050062 · 2010-01-01 · 1 site observation
COMPLETED
Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After DiscontinuationNCT01120366 · 2009-10-01 · 1 site observation
COMPLETED
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung CancerNCT00662597 · 2008-04-01 · 1 site observation
TERMINATED
Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary DiseaseNCT02177318 · 2005-04-01 · 1 site observation
COMPLETED
Special Survey on Parkinson's Disease Patients Treated Long-term Use of PramipexoleNCT00615914 · 2004-02-01 · 1 site observation
COMPLETED
Special Survey on PD Patients With Renal DysfunctionNCT00613756 · 2004-02-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.